Rachel Collins, MD, MBA
Hospital ResidentCards
About
Research
Publications
2025
A Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy
Goodman R, Burnette H, Johnson D. A Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy. 2025, 449-454. DOI: 10.1007/978-3-031-83533-9_56.Peer-Reviewed Original ResearchCharacterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
Fletcher K, Goodman R, Lawless A, Woodford R, Fa’ak F, Tipirneni A, Patrinely J, Yeoh H, Rapisuwon S, Haydon A, Osman I, Mehnert J, Long G, Sullivan R, Carlino M, Menzies A, Dewan A, Johnson D. Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors. JAMA Dermatology 2025, 161: 555-557. PMID: 40072456, PMCID: PMC11904794, DOI: 10.1001/jamadermatol.2025.0025.Peer-Reviewed Original ResearchSafety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Nassar A, Alaiwi S, Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman R, Johnson D, Grynberg S, Shapira R, Kwan J, Woodford R, Long G, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang E, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Herrera M, Foderaro S, Nana F, Kim C, Sackstein P, Parikh K, Desai A, Smith C, Cortellini A, Pinato D, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Gallegos J, Trent J, Nusrat S, Malvar C, McKay R, Neilan T, Choueiri T, Naqash A. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal For ImmunoTherapy Of Cancer 2025, 13: e009364. PMID: 40032601, PMCID: PMC11877189, DOI: 10.1136/jitc-2024-009364.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitor initiationImmune checkpoint inhibitorsTreatment-related adverse eventsObjective response rateProgression-free survivalCardiac metastasisOverall survivalRetrospective studyAnti-cytotoxic T-lymphocyte antigen 4Dose of immune checkpoint inhibitorsEfficacy of immune checkpoint therapyAnti-programmed death-1International multicenter retrospective studyMulticenter international retrospective studyT-lymphocyte antigen-4Non-small cell lung cancerMedian follow-up timeClinical outcomes of patientsICI-based regimensMultiple cardiac metastasesSolid Tumors V.1.1Immune checkpoint therapyResponse Evaluation CriteriaInternational retrospective studyMulticenter retrospective studyUrban versus non-urban patient geographic status impacts melanoma survival: a surveillance, epidemiology, and end results (SEER) database study
Thakker S, Belzberg M, Gulati N, Goodman R, Gulati N. Urban versus non-urban patient geographic status impacts melanoma survival: a surveillance, epidemiology, and end results (SEER) database study. Archives Of Dermatological Research 2025, 317: 494. PMID: 40009240, DOI: 10.1007/s00403-025-04015-2.Peer-Reviewed Original Research
2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Woodford R, McKeown J, Hoeijmakers L, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank C, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson D, Mcarthur G, Rutkowski P, Neyns B, Sullivan R, Weber J, Carlino M, Ascierto P, Lo S, Long G, Menzies A. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. European Journal Of Cancer 2024, 212: 115055. PMID: 39366209, DOI: 10.1016/j.ejca.2024.115055.Peer-Reviewed Original ResearchConceptsAnti-PD-1 based therapyAnti-PD-1 therapyAnti-PD-1Adjuvant anti-PD-1 therapyBased therapyStage II-IV melanomaMedian time to recurrenceMedian follow-up timeManagement of recurrenceTime to recurrenceTime of recurrenceFollow-up timeRetrospective cohort studyAnti-CTLA4LR recurrenceLocal therapyMelanoma patientsRecurrent diseaseSystemic therapyMelanoma recurrenceMedian ageCohort studyStage IVRecurrenceStage III52868 Melanoma Survival Outcomes in Metropolitan and Non-Metropolitan Populations: A Surveillance, Epidemiology, and End Results (SEER) Database Study
Thakker S, Gulati N, Goodman R, Belzberg M, Gulati N. 52868 Melanoma Survival Outcomes in Metropolitan and Non-Metropolitan Populations: A Surveillance, Epidemiology, and End Results (SEER) Database Study. Journal Of The American Academy Of Dermatology 2024, 91: ab62. DOI: 10.1016/j.jaad.2024.07.256.Peer-Reviewed Original ResearchPrimary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study
Goodman R, Jung S, Fletcher K, Burnette H, Mohyuddin I, Irlmeier R, Ye F, Johnson D. Primary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study. Cancers 2024, 16: 2355. PMID: 39001417, PMCID: PMC11240575, DOI: 10.3390/cancers16132355.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRetrospective cohort studyCutaneous melanomaAssociated with responseMelanoma patientsImmunotherapy responseTreated with immune checkpoint inhibitorsCohort studySingle-center retrospective cohort studyAssociated with shorter PFSAnti-PD-1 monotherapyAssociated with inferior outcomesBiomarkers of immunotherapy responsePrimary tumor characteristicsPrimary tumor featuresAdvanced melanoma patientsResponse to immunotherapySingle-center designCheckpoint inhibitorsShorter PFSAdvanced melanomaTumor characteristicsPrimary melanomaMutation statusMetastatic stage
2023
Accuracy and Reliability of Chatbot Responses to Physician Questions
Goodman R, Patrinely J, Stone C, Zimmerman E, Donald R, Chang S, Berkowitz S, Finn A, Jahangir E, Scoville E, Reese T, Friedman D, Bastarache J, van der Heijden Y, Wright J, Ye F, Carter N, Alexander M, Choe J, Chastain C, Zic J, Horst S, Turker I, Agarwal R, Osmundson E, Idrees K, Kiernan C, Padmanabhan C, Bailey C, Schlegel C, Chambless L, Gibson M, Osterman T, Wheless L, Johnson D. Accuracy and Reliability of Chatbot Responses to Physician Questions. JAMA Network Open 2023, 6: e2336483. PMID: 37782499, PMCID: PMC10546234, DOI: 10.1001/jamanetworkopen.2023.36483.Peer-Reviewed Original ResearchConceptsMedical informationHealth care efficiencyAccessibility of medical informationCross-sectional studyMedical queriesHealth professionalsPhysician specialistsCare efficiencyMain OutcomesPhysician questionsMann-Whitney U testComplex decision-makingPhysiciansKruskal-Wallis testMedical responseMedical questionsInitial scoreClinical settingMedian accuracy scoresScoresAccuracy scoresSpecialtyCompleteness scoreMann-WhitneyU testLong-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Goodman R, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long G, Sullivan R, Carlino M, Atkinson V, Trojanello C, Ascierto P, Schadendorf D, Warburton L, Menzies A, Santinami M, Johnson D. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal Of Cancer 2023, 194: 113354. PMID: 37827067, PMCID: PMC10843257, DOI: 10.1016/j.ejca.2023.113354.Peer-Reviewed Original ResearchConceptsMedian Follow-UpBRAF/MEK inhibitorsFollow-upAdverse eventsRetrospective multicenter cohort studyBRAF/MEK inhibitor therapyCardiac adverse eventsMulticenter cohort studyLong-term toxicityLong-term outcomesLong-term safetyAntitumor responseProgression-FreeAdvanced melanomaDiscontinued therapyInhibitor therapySystemic therapyImmune therapyPrimary cancerDiscontinued treatmentTreatment startBRAF/MEKCohort studyLow-gradeActive treatmentPublic Health Risks, Dermatological Manifestations, and Environmental Justice Associated With Vinyl Chloride Exposure: Narrative Review
Goodman R, Mittal L, Parker E. Public Health Risks, Dermatological Manifestations, and Environmental Justice Associated With Vinyl Chloride Exposure: Narrative Review. JMIR Dermatology 2023, 6: e48998. PMID: 37676716, PMCID: PMC10514763, DOI: 10.2196/48998.Peer-Reviewed Original ResearchImpact communities of colorImproved public health measuresPublic healthLong-term health impactsLow socioeconomic statusNarrative reviewPublic health measuresPublic health officialsHealth disparitiesExposure-related diseasesSocioeconomic statusGrey literatureKeyword search termsCommunities of colorHealth measuresEvidence-basedVulnerable populationsMinority populationsHealth officialsLower-incomeVC exposureSearch termsHealthChronic dermatological conditionsHealth implications